#217 Parallel Session - Aid Experience in the Real-World - in the United Kingdom

Published Date: 21st February 2023

Publication Authors: Furlong NJ

Abstract
AID experience in the real‐world in the United Kingdom Background Hybrid closed loop (HCL) technology automates insulin delivery and improves outcomes in people living with Type 1 diabetes. We report real‐world outcomes from adults with Type 1 diabetes with raised HbA1c despite insulin pump therapy and flash glucose monitoring. Methods A national clinical audit programme collected routine, anonymised clinical data submitted to a secure online tool. Reported outcomes include HbA1c, key glucose sensor metrics; Diabetes Distress Score; Gold Score; event rates (hospital admissions, paramedic callouts and severe hypoglycaemia) and user opinion of HCL. Results Follow up data were available from 520 HCL users; median age 40 (IQR 29‐50) years, 67% female, mean diabetes duration of 21 (IQR 15‐30) years, 85% white British. Baseline HbA1c 78.9 ± 9.1mmol/mol [9.4 ± 0.8%] reduced to 62.1 ± 9.1mmol/mol [7.8 ± 0.8%] at 5.1 (IQR 3.9‐6.6) months median follow up. Mean adjusted HbA1c reduced by ‐18.1mmol/mol (95% CI ‐16.5, ‐19.6; P < 0.001) [1.7% (95% CI 1.5, 1.8, P < 0.001)]. Time in range (3.9‐10mmol/l) increased from 34.2% to 61.8% (P < 0.001), time below range (<3.9mmol/l) reduced from 2.1% to 1.6% (P < 0.001). The proportion reporting diabetes‐related distress reduced from 69.0% to 22.5%(P = 0.001). Gold score reduced from 2.2 to 1.6 (P < 0.001). Almost all (96.3%, 549/570) would recommend HCL to others with diabetes; 94.7% (540/570) reported that the system had a positive impact on their quality of life. No significant increases in hospital admissions/paramedic callouts were found. Conclusion The NHS England pilot of HCL therapy led to substantial improvements in HbA1c, time in range and time below range over 5 months of follow up. The prevalence of diabetes related distress improved. Almost all reported a positive impact on quality of life and would recommend the use of HCL system to other people living with diabetes.

 

Wilmot, E; Furlong, N et al. (2023). #217 Parallel Session - Aid Experience in the Real-World - in the United Kingdom. Diabetes Technology & Therapeutics. 25(S2), p.A10. [Online]. Available at: https://doi.org/10.1089/dia.2023.2525.abstracts [Accessed 20 March 2023]

 

« Back